References

1-215

1. Rosenberg JE, O'Donnell PH, Balar AV, et al. Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy. *J Clin Oncol.* 2019;37(29):2592-2600.

2. Deng H, Shi H, Chen L, et al. Over-expression of nectin-4 promotes progression of esophageal cancer and correlates with poor prognosis of the patients. *Cancer Cell Int*.2019;19:106-119.

3. Padcev™ (enfortumab vedotin-ejfv) for injection, for intravenous use [package insert]. Astellas Pharma US, Northbrook, IL. Revised 12/2023.

4. Clinical Pharmacology Compendia™. Tampa FL: Gold Standard, Inc. Enfortumab vedotin. 2024.

5. Micromedex® Solutions Compendia. 2024. Enfortumab vedotin.

6. National Comprehensive Cancer Network (NCCN). NCCN Drugs and Biologics Compendium®. 2024. Enfortumab vedotin.

7. Enfortumab vedotin-ejfv In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated October 19, 2020.

8. Hoimes CJ, Flaig TW, Milowsky MI, et al. Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer. *J Clin Oncol*. 2023;41(1):22-31.